Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019101 | 1.00 | ADRA2A (0.36) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16017788 | 1.00 | ADRA2A (0.36) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16017781 | 1.00 | ADRA2A (0.36) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16017779 | 0.89 | ADRA2A (0.43) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16017894 | 0.89 | ADRA2A (0.43) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16017768 | 0.89 | PRKCA (0.36) | ADRA2AADRA1AMAPTBLMPRKCA | |
| SCHEMBL16017769 | 0.89 | ADRA2A (0.43) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL18116116 | 0.88 | ADRA2A (0.42) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16019103 | 0.87 | HTR2C (0.41) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16019695 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256658-A1 | Antibiotic Conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256658-A1 | Antibiotic Conjugates | NAALAD2, DNPEP, ENGASE | ADRA2A 4665/4885ADRA1A 4225/4885MAPT 2636/4885 |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | CYP21A2, CHP1, CYP51A1 | ADRA2A 2407/4885ADRA1A 1692/4885MAPT 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.